Fast Track designation is a modest positive for development timeline optionality but does not change the binary risk of Phase 1b data expected in 2027. Monitor FORTIFY enrollment updates and any future partnership interest; the stock's low liquidity and negative historical drift suggest limited near-term catalyst from this procedural milestone alone.
Drug in focus
PLRX drug pipeline →PLN-101095
● Neutral Named in this press release- Impact
- Phase
- Phase 1b
- Time to market
- At least 3-5 years away, if ever. The drug is still in Phase 1b testing. Even under a Fast Track pathway, it would need to complete Phase 2 and Phase 3 trials before any approval filing.
- Next catalyst
- None dated
What to watchPLN-101095 is an early-stage oncology asset at a cash-strapped company that already lost its lead pipeline drug. Watch for FORTIFY enrollment completion updates and any efficacy signals from the Phase 1b expansion cohorts. The stock is trading near cash value, so positive data could drive a meaningful rally, but the company's financial runway and lack of analyst coverage are serious headwinds. No near-term binary catalyst is on the calendar.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 18 $1.15entry
- T+1 · 3mo ago +1.74%α +1.53% · $1.17
- T+5 · 3mo ago +3.48%α +3.68% · $1.19
- T+20 · 2mo ago −0.43%α +0.55% · $1.15
- T+60 · 6d ago −31.68%α −29.64% · $0.7857
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pliant Therapeutics announced FDA Fast Track designation for PLN-101095, an oral dual integrin inhibitor for ICI-refractory solid tumors. The designation provides regulatory benefits (rolling NDA, priority review eligibility) but is a procedural milestone, not a clinical data readout.
Key Facts
- FDA Fast Track designation granted for PLN-101095 in combination with pembrolizumab for ICI-refractory solid tumors
- PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins
- Currently being evaluated in Phase 1a/1b FORTIFY trial (NCT06270706) with data expected in 2027
- Fast Track benefits include frequent FDA meetings, rolling NDA submission, and priority review eligibility
- Company market cap is approximately $66M with 0% analyst bullishness (6 Hold, 4 Sell/Strong Sell)
Financial Impact
No financial figures disclosed; Fast Track is a procedural designation with no direct revenue or cost impact
Risk Factors
- Fast Track does not guarantee approval or accelerate clinical timelines; the designation is procedural
- PLN-101095 is in early-stage Phase 1a/1b with no efficacy data yet; clinical failure risk remains high
- Company has $66M market cap with 0% analyst buy ratings, indicating low institutional conviction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3346838 |
Track record
8 reports on PLRX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.6970 Now $0.6930 −0.57% settles Feb 11
- Aug 18, 202612w ago Press Release Bullish 4/10 Viewing Entry $1.15 to $0.7857 Now $0.6930 −39.74% ▼ −31.68% −29.64% vs SPY
- May 11, 202627w ago 8-K Neutral 4/10 No price data
- May 11, 202627w ago Press Release Bearish 6/10 Entry $1.18 to $1.05 Now $0.6930 +41.27% ▲ +11.02% +15.40% vs SPY
- Apr 17, 202630w ago 8-K Mixed 6/10 Entry $1.29 to $1.12 Now $0.6930 −46.28% ▼ −13.18% −19.96% vs SPY
- Apr 7, 202632w ago EFFECT Neutral 4/10 Entry $1.31 to $1.17 Now $0.6930 −47.10% ▼ −10.69% −23.96% vs SPY
- Mar 11, 202635w ago 8-K Bullish 7/10 Entry $1.41 to $1.15 Now $0.6930 −50.85% ▼ −18.44% −29.14% vs SPY
- Mar 3, 202636w ago 8-K Neutral 3/10 Entry $1.29 to $1.25 Now $0.6930 −46.28% ▼ −3.10% −13.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers